Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: Influence of gender, sexual orientation and race

HIV Medicine

Volumn 12, Issue 3, 2011, Pages 183-191

  Menezes, P ^a,b   Eron, J J ^a   Leone, P A ^a,b   Adimora, A A ^a,b   Wohl, D A ^a   Miller, W C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

Clinical trials; Gender; Highly active antiretroviral therapy; HIV infection; Race; Sexual orientation

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; ETHNICITY; FEMALE; GENDER; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PREVALENCE; PRIORITY JOURNAL; RACE; SEXUAL BEHAVIOR; SEXUAL ORIENTATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; FEMALE; GENDER IDENTITY; HIV INFECTIONS; HUMANS; MALE; PATIENT SELECTION; SEXUAL BEHAVIOR;

EID: 79551609303     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00867.x     Document Type: Article

References (42)

1. Garber M, Hanusa BH, Switzer GE et al. HIV-infected African Americans are willing to participate in HIV treatment trials. J Gen Intern Med 2007; 22: 17-42.
2. El-Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA 1992; 267: 954-957.
3. Fayter D, McDaid C, Eastwood A. A systematic review highlights threats to validity in studies of barriers to cancer trial participation. J Clin Epidemiol 2007; 60: 990-1001.
4. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
5. Gulick RM, Ribaudo HJ, Shikuma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-1861.
6. Diaz T, Chu SY, Sorvillo F et al. Differences in participation in experimental drug trials among persons with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 562-568.
7. Gifford AL, Cunningham WE, Heslin KC et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002; 346: 1373-1382.
8. Hankins C, Lapointe N, Walmsley S. Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group. CMAJ 1998; 159: 1359-1365.
9. Madge S, Mocroft A, Wilson D et al. Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Med 2000; 1: 212-218.
10. Moore DA, Goodall RL, Ives NJ et al. How generalizable are the results of large randomized controlled trials of antiretroviral therapy? HIV Med 2000; 1: 149-154.
11. Stone VE, Mauch MY, Steger K et al. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med 1997; 12: 150-157.
12. Sullivan PS, McNaghten AD, Begley E et al. Enrollment of racial/ethnic minorities and women with HIV in clinical research studies of HIV medicines. J Natl Med Assoc 2007; 99: 242-250.
13. US Food and Drug Administration, Department of Health and Human Services Guidelines for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed Reg 1993; 58: 39406-39416.
14. NIH Revitalization Act, Subtitle B, Part1, Sec 131-133, June 10, 1993.
15. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Federal Register, Part VIII (59 FR 14508-14513), March 28, 1994.
16. Napravnik S, Edwards D, Stewart P et al. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40: 34-40.
17. Napravnik S, Eron JJ et al. Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006; 18 (Suppl 1): S45-S50.
18. Centers for Disease Control 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Available at (accessed 15 August 2008).
19. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3: 21.
20. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998; 316: 989-991.
21. McNutt LA, Wu C, Xue X et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003; 157: 940-943.
22. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-706.
23. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: J. Wiley & Sons, 1987.
24. Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models. Am Stat 2007; 61: 79-90.
25. Patrician PA. Multiple imputation for missing data. Res Nurs Health 2002; 25: 76-84.
26. Royston P. Multiple Imputation using ICE. UCLA: Academic Technology Services, Statistical Consulting Group. Available at (accessed 1 June 2008).
27. Mills E, Cooper C, Guyatt G et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004; 18: 2235-2242.
28. Medicaid in North Carolina Annual Report. North Carolina Department of Health and Human Services. Division of Medical Assistance. Available at (accessed 20 May 2008).
29. Kaiser Commission on Medicaid and the Uninsured analysis of 2004 MSIS data, 2007. Available at (accessed 15 August 2008).
30. Kates JMJ, Patel P. Medicaid and HIV/AIDS: A Gender Analysis of the Experiences of HIV-Infected Medicaid Beneficiaries in Four States. Abstract at the Academy of Health Services Research Health Policy Meeting. 2002.
31. Gandhi M, Bacchetti P, Miotti P et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35: 313-322.
32. Ickovics JR, Forsyth B, Ethier KA et al. Delayed entry into health care for women with HIV disease. AIDS Patient Care STDS 1996; 10: 21-24.
33. Corbie-Smith G, Thomas SB, Williams MV et al. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med 1999; 14: 537-546.
34. Sengupta S, Strauss RP, DeVellis R et al. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000; 24: 275-284.
35. Wendler D, Kington R, Madans J et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med 2006; 3: e19.
36. Baquet CR, Commiskey P, Daniel Mullins C et al. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev 2006; 30: 24-33.
37. Comis RL, Colaizzi DD, Miller JD. Barriers to Cancer Clinical Trials (CCT) Participation: "We have met the enemy and he is us". American Society of Clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition). Journal of Clinical Oncology 2007; 25 (Suppl): 18S [Abstract 6567].
38. Albrecht TL, Blanchard C, Ruckdeschel JC et al. Strategic physician communication and oncology clinical trials. J Clin Oncol 1999; 17: 3324-3332.
39. Pence BW, Reif S, Whetten K et al. Minorities, the poor, and survivors of abuse: HIV-infected patients in the US deep South. South Med J 2007; 100: 1114-1122.
40. Reif S, Whetten K, Ostermann J et al. Characteristics of HIV-infected adults in the Deep South and their utilization of mental health services: a rural vs. urban comparison. AIDS Care 2006; 18 (Suppl 1): S10-S17.
41. Whetten-Goldstein K, Nguyen TQ, Heald AE. Characteristics of individuals infected with the human immunodeficiency virus and provider interaction in the predominantly rural Southeast. South Med J 2001; 94: 212-222.
42. Medical Research Council of Canada. Final Report: Advisory committee on Women in Clinical Trials. Ottawa: The Council, 1996.